Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment fo...
Journal Information
Vol. 152. Issue 11.
Pages 438-441 (June 2019)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 152. Issue 11.
Pages 438-441 (June 2019)
Brief report
DOI: 10.1016/j.medcle.2018.09.012
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2
Eficacia de los inhibidores del cotransportador sodio glucosa tipo 2 como tratamiento adyuvante en pacientes con diabetes tipo 2 tratados con insulina
Visits
...
Pedro Pujantea,1,
Corresponding author
pedropujanteal@gmail.com

Corresponding author.
, Jessica Aresa,1, Carmen Maciáb, Raúl Rodriguez Escobedoa, Edelmiro Menéndeza, Elías Delgadoa
a Hospital Central de Asturias, Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
b Hospital San Agustín, Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avilés, Asturias, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Characteristics of patients as a function of their baseline HbA1c blood concentration.
Table 2. Prior non-insulin antihyperglycemic treatments.
Table 3. Changes in insulin dose, HbA1c, metabolic and anthropometric parameters and blood pressure after administration of SGLT2 inhibitors for four months to patients subjected to standard T2D treatments.
Show moreShow less
Abstract
Objective

To analyze the effect of sodium glucose cotransporter 2 (SGLT2) inhibitors in a group of insulin-dependent type 2 diabetes mellitus (T2D) patients.

Patients and methods

One hundred and five insulin treated T2D patients were enrolled. Primary endpoints were: fasting plasma glucose, HbA1c, weight, total insulin doses (TDI), total basal insulin (TDB) and total rapid insulin (TDR). Secondary variables were: total cholesterol, LDL cholesterol (cLDL), HDL cholesterol (cHDL), triglycerides and systolic (SBP) and diastolic (DBP) blood pressure. Safety and tolerance were evaluated through the appearance of severe hypoglycemia, ketoacidosis and infections.

Results

After 4 months follow-up, a 0.7 (1.0)% HbA1c reduction was found, accompanied by a −2.8 (11.5) UI/day TDI decrease. Weight dropped for 73.7% of patients, with an average −2.0 (2.7) kg reduction. A global cHDL increase was noted after treatment, while no differences were observed for total cholesterol, triglycerides or cLDL. SBP dropped significantly, but no change in DBP was observed.

Conclusion

The use of SGLT2 inhibitors in insulin treated T2D patients resulted in reduction of HbA1c, which was associated to weight loss, cHDL increase and SBP decrease.

Keywords:
Diabetes
Insulin
Obesity
SGLT2
Real life
Resumen
Objetivo

Analizar el efecto de los inhibidores del cotransportador sodio glucosa tipo 2 (iSGLT2) en grupo de pacientes con diabetes mellitus tipo 2 (DM2) tratados con insulina.

Pacientes y métodos

Seleccionamos ciento cinco pacientes con diabetes tipo 2 tratados con insulina. Los objetivos primarios: glucosa plasmática ayunas, HbA1c, peso, dosis total de insulina (DTI), dosis de insulina basal (DTB), dosis de insulina rápida (DTR). Como secundarios: Colesterol total, LDL colesterol (cLDL), HDL colesterol (cHDL), triglicéridos and tensión sistólica (TAS) and diastólica (TAD). La seguridad y tolerancia se valoró como hipoglucemia, cetoacidosis o infecciones.

Resultados

Tras 4 meses, la HbA1c se redujo en 0,7 (1,0)% acompañado de una disminución en DTI de −2,8 (11,5) UI/día. El 73,7% de los pacientes perdieron peso, con un descenso medio de −2,0 (2,7) kg. El cHDL aumentó, mientras que no observamos diferencias en el colesterol total, triglicéridos o cLDL. TAS disminuyó significativamente sin observar cambios en TAD.

Conclusión

El uso de iSGLT2 en pacientes con DM2 tratados con insulina reduce la HbA1c asociando pérdida de peso, aumento enl cHDL y descenso en TAS.

Palabras clave:
Diabetes
Insulina
Obesidad
SGLT2
Vida real

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos